TNFRSF17 and neoplasm: Because BCMA loss at a genetic level renders tumor cells resistant both to BCMA CAR-T therapy and to the effects of GSIs (29, 30), several groups have explored multi-antigen targeting to expand the versatility of CAR-T cells.